KPTI•benzinga•
Karyopharm Says Phase 3 XPORT-EC-042 Trial Of Selinexor As Maintenance Therapy In Advanced or Recurrent TP53 Wild-Type Endometrial Cancer To Focus Enrollment Patients with Either pMMR Tumors or Patients with dMMR Tumors that are Medically Ineligible for C
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 19, 2025 by benzinga